HRT cuts risk of repeat knee/hip replacement surgery by 40 percent
Hormone replacement therapy (HRT) taken regularly for six months after a knee or hip replacement seems to cut the risk of repeat surgery by around 40%, indicates a large population based study published online in the Annals of the Rheumatic Diseases.
National data for England and Wales indicate that more than 2% of procedures typically have to be repeated within three years, primarily because of osteolysis (75% of cases).
Osteolysis occurs when particles from the implant seep into the surrounding tissue, prompting an inflammatory response which then destroys the bone around the implant.
And joint replacement surgery rates are set to rise substantially as the population ages and the prevalence of obesity increases, say the authors. The research team assessed the likelihood of repeat joint replacement surgery among women who required a first knee or hip replacement between 1986 and 2006.
The women's details had been entered into the primary care General Practice Research Database (GPRD), which holds millions of anonymised medical records for patients across the UK.
More than 21,000 eligible women who met the criteria had not used HRT, while more than 3500 had done so for at least six months, providing matched samples of 2700 HRT users and 8100 women who had not used HRT.
The risk of repeat surgery was tracked in both sets of women for a minimum of three years.
Those who had taken HRT regularly for six months or more after their surgery were 38% less likely to require repeat surgery than were those who had not done so.
Furthermore, those who regularly took HRT for 12 months or more after their procedure were more than 50% less likely to need further surgery during the three year monitoring period.
Taking HRT before surgery, however, made no difference to the risk of implant failure, the findings showed.
The findings held true even after taking account of other influential factors, including use of drugs that can impair bone turnover.
Low levels of the female hormone oestrogen have been implicated in bone thinning and loss, while HRT is thought to help conserve bone thickness. But this is the first study to show that it can help prevent repeat surgery in women who have undergone hip/knee replacement, say the authors.